What is HC Wainwright’s Forecast for ACRS FY2024 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at HC Wainwright lifted their FY2024 earnings estimates for Aclaris Therapeutics in a report issued on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.58) per share for the year, up from their prior forecast of ($0.66). HC Wainwright currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2024 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.59) EPS.

ACRS has been the subject of several other reports. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Leerink Partnrs upgraded shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 19th. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $2.00 to $7.00 in a research note on Tuesday, November 19th. BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, November 19th. Finally, Cantor Fitzgerald raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, November 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.00.

Aclaris Therapeutics Stock Up 0.3 %

NASDAQ ACRS opened at $2.90 on Wednesday. Aclaris Therapeutics has a twelve month low of $0.86 and a twelve month high of $5.17. The business has a 50-day moving average price of $2.79 and a 200-day moving average price of $1.76. The firm has a market cap of $207.15 million, a price-to-earnings ratio of -5.58 and a beta of 0.44.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million during the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

Hedge Funds Weigh In On Aclaris Therapeutics

Several large investors have recently modified their holdings of ACRS. Stonepine Capital Management LLC bought a new stake in Aclaris Therapeutics in the second quarter worth $2,120,000. Trium Capital LLP purchased a new stake in shares of Aclaris Therapeutics in the second quarter valued at $2,081,000. BML Capital Management LLC lifted its holdings in shares of Aclaris Therapeutics by 9.7% in the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after acquiring an additional 1,261,866 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Aclaris Therapeutics during the 3rd quarter valued at about $1,053,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 216,826 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

Insiders Place Their Bets

In related news, Director Anand Mehra acquired 666,666 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the transaction, the director now directly owns 710,030 shares in the company, valued at approximately $1,597,567.50. This trade represents a 1,537.37 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.